ARTICLE | Regulation

Salvage in psoriasis?

Why brodalumab fills a small but important niche in psoriasis

July 25, 2016 7:00 AM UTC

A hint of suicidality risk and insufficient differentiation could mean brodalumab is relegated to the last lines of the biologics for psoriasis. But that might be OK given the meager price Valeant Pharmaceuticals International Inc. paid to acquire the candidate after AstraZeneca plc bowed out.

The human IgG2 mAb against IL-17 receptor (IL17R; IL17RA) took a tortuous path to the July 19 meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee. ...